AOA Dx Closes $7 million Funding Round to Bring the First Accurate Early Detection Test for Ovarian Cancer to Market

AOA Dx Inc is proud to announce that they have closed both of their seed rounds totaling a $7 million funding round led by Avestria Ventures, AlleyCorp, The Helm, RH Capital, Olive Tree Capital, Tencent and other notable investors.

The funding will be used to further develop the next generation of AOA’s ovarian cancer detection technology, AKRIVIS GD™ and expand their growing team. Currently, there are no reliable ovarian cancer biomarkers that detect early stage disease.

AOA Dx Welcomes Women’s Health Industry Leader Surbhi Sarna as an Independent Board Member

AOA Dx is excited to announce the appointment of Surbhi Sarna as an Independent Board Member. Sarna is most recently known for becoming Y Combinator’s first-ever partner for healthcare and biotech.

Sarna is the founder and former CEO of nVision Medical, a medical device company that to date, is the only device cleared by the FDA to collect cells from the fallopian tube, the known site of the most lethal forms of ovarian cancer. nVision Medical was acquired by Boston Scientific in 2018 for $275 million.

AOA Dx Featured in The Journal of Precision Medicine

AOA Dx Inc is proud to annouce that they were featured in “The Journal of Precision Medicine, titled “Tumor Glycolipids, a New Frontier for Early Detection and Precision Medicine in Ovarian Cancer and Other Malginancies”. The paper was authored by AOA’s Chief Scientific Officer H. Uri Saragovi, PHD, AOA’s Co-Founder and Chief Business Officer Anna Milik Jeter and Samantha A. Yee, a PhD cancidate at UT San Antonio.

AOA Dx Signs Exclusive License Agreement with Professor H. Uri Saragovi to Secure a Suite of IP Related To Early Detection of Cancer Through a Novel Quantification of Tumor Ganglioside in Liquid Biopsies

AOA Dx Inc has signed an Exclusive License Agreement with Professor H. Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University, to secure a suite of IP related to utilizing gangliosides for early cancer detection through liquid biopsies.

Chief Scientific Officer of AOA Dx Has Been Awarded $650,000 by the Canadian Institute of Health Research

AOA Dx Inc is proud to announce that their Chief Scientific Officer, Prof. H. Uri Saragovi has been awarded a $650,000 CAD grant for further development of a proprietary liquid biopsy test for early stage ovarian cancer. AOA has an exclusive license agreement to the proprietary technology. In addition to serving as AOA Dx’s Chief Scientific Officer, Prof. Saragovi is the Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University

AOA Dx Gets Y Combinator’s Backing and Raises $2.5 Million Seed Round to Develop First Non-invasive Ovarian Cancer Liquid Biopsy Diagnostic Test 

AOA Dx Inc is proud to announce that they have been accepted to Y Combinator’s 2021 summer cohort and have closed a $2.5 million seed round to develop AKRIVIS GD   , a liquid biopsy test that is set to revolutionize the future of ovarian cancer diagnostics.  AOA Dx has been working in close collaboration with world renowned cancer researcher Professor H. Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University.